Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
The effect of Nintendo(R) Wii(R) on balance in people with multiple sclerosis: a pilot randomized control study.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Stress and the risk of multiple sclerosis.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
First NW patient to receive OHSU/VAMC-invented MS drug
Stress signaling etches heritable marks on chromatin.
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Time limited immunomodulatory functions of transplanted neural precursor cells.

Pages